Mutual Funds Buy Biocon, PB Fintech: July Inflows

Indian mutual funds significantly ramped up investments in small and mid-cap stocks in July 2026, with Biocon and PB Fintech emerging as key beneficiaries. Biocon alone attracted substantial net inflows of ₹3,300 crore from fund managers.

• Biocon net mutual fund inflows: ₹3,300 crore
• Institutional stake acquired in Biocon: 5.64% (sold by Mylan/Viatris)
• HDFC Mutual Fund holding in PB Fintech: increased to 5.02%
• Nifty Pharma index gain (July): nearly 20%
• Biocon shares rise (July): 18%

The surge in Biocon’s inflows was primarily driven by institutional investors acquiring a 5.64% stake, facilitated through block deals by Mylan, a subsidiary of Viatris. PB Fintech, parent company of Policybazaar, also saw heightened institutional interest with HDFC Mutual Fund increasing its stake.

This aggressive accumulation in mid-cap stocks coincided with the Nifty Pharma index gaining nearly 20% by the end of July, while Biocon shares rose 18% in the same period. The broader trend indicates robust investor appetite for smaller companies, reflected in the small and mid-cap mutual fund category reaching an 11-month high in new investor accounts.

Valuation Concerns Emerge

Despite the strong buying activity, investors are advised to maintain a balanced perspective. The mid-cap sector currently faces significant valuation concerns, with many analysts warning of inflated prices across numerous companies.

Elevated valuations inherently make companies more susceptible to negative market news or any missed performance targets. For Biocon, this is particularly relevant given its recent financial performance.

Biocon reported a substantial 63.45% decline in its consolidated net profit for the quarter ending March 2026. The stock’s future trajectory will hinge on the company’s ability to demonstrate improved operational efficiency and profit margins to justify its higher valuation.

Moving forward, the market’s focus will shift towards upcoming quarterly results. These earnings reports will be critical indicators to determine if the recent price appreciation in these companies is underpinned by actual business growth or merely by prevailing liquidity and market momentum.